Vol 1, No 2 (June 30, 2012): Translational Lung Cancer Research

Maintenance Therapy1

Gefitinib NSCLC maintenance therapy
Martin H. Cohen
PDF Pages: 94-95 Full Text (2500) Open Access Get Permission
Biomarkers in the selection of maintenance therapy in non-small cell lung cancer
Nichole T. Tanner, Carol A. Sherman, Gerard A. Silvestri
PDF Pages: 96-98 Full Text (3997) Chinese (2901) Open Access Get Permission
A strong step forward in maintenance therapy for non-small cell lung cancer treatment
Edgardo S. Santos, Tarek Mekhail
PDF Pages: 99-101 Full Text (2997) Open Access Get Permission
INFORM; C-TONG 0805: A multicenter, double blind randomizedphase III trial of maintenance gefitinib compared to placebo inadvanced non-small cell lung cancer
Thomas E. Stinchcombe
PDF Pages: 102-104 Full Text (2779) Open Access Get Permission
Maintenance therapy in non-small cell lung cancer
Gerald Schmid-Bindert
PDF Pages: 105-110 Full Text (17547) Open Access Get Permission

Review Articles

From tissue to molecular phenotyping: Pre-analytical requirements
Thomas R. Muley, Felix JF. Herth, Philipp A. Schnabel, Hendrik Dienemann, Michael Meister
PDF Pages: 111-121 Full Text (15454) Open Access Get Permission
Targeting angiogenesis in lung cancer-Pitfalls in drug development
Wolfgang Hilbe, Christian Manegold, Andreas Pircher
PDF Pages: 122-128 Full Text (6089) Open Access Get Permission

Original Article

Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis
Hui Gao, Xin Ding, Dong Wei, Peng Cheng, Xiaomei Su, Huanyi Liu, Fahad Aziz, Daoyuan Wang, Tao Zhang
PDF Pages: 129-144 Full Text (4088) Open Access Get Permission

Perspectives

EGFR IHC score for selection of cetuximab treatment: Ready for clinical practice?
Martin Früh, Miklos Pless
PDF Pages: 145-146 Full Text (6285) Open Access Get Permission
TKIs in NSCLC: The down of a new era?
Adrianni Charpidou, Kostas N Syrigos
PDF Pages: 147-148 Full Text (2245) Open Access Get Permission
Treating acquired resistance to EGFR-tyrosine kinase inhibitors: Still a work in progress
Nathan A. Pennell
PDF Pages: 149-151 Full Text (3630) Open Access Get Permission
Is there a third line option after chemotherapy and TKI failure in advanced non-small cell lung cancer?
Jacques De Grève, Lore Decoster, David van Brummelen, Caroline Geers, Denis Schallier
PDF Pages: 152-154 Full Text (3595) Open Access Get Permission

Editorials

TRAIL apoptotic pathway-targeted therapies for NSCLC
Anita C. Bellail, Chunhai Hao
PDF Pages: 155-157 Full Text (4711) Open Access Get Permission
Dulanermin in cancer therapy: Still much to do
Cristina Quintavalle, Gerolama Condorelli
PDF Pages: 158-159 Full Text (6204) Open Access Get Permission
EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMation
Lorenza Landi, Federico Cappuzzo
PDF Pages: 160-162 Full Text (2386) Open Access Get Permission

Disclosure:

1.  The series “Maintenance Therapy” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding.